Altimmune, Inc

Altimmune, Inc

GAITHERSBURG, Md., May perhaps 05, 2022 (Globe NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a medical-phase biopharmaceutical organization, currently announced that it will report its to start with quarter 2022 economic results on Thursday, May well 12, 2022 and will present a business update.

Altimmune administration will host a meeting contact at 8:30 am E.T. on Might 12 to talk about money outcomes and supply a company update.

Meeting Contact Information:

About Altimmune

Altimmune is a clinical-phase biopharmaceutical enterprise targeted on the progress of novel peptide-based therapeutics for the remedy of obesity and liver health conditions. The company‚Äôs lead product or service prospect, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is getting developed for the remedy of being overweight and NASH. In addition, Altimmune is acquiring HepTcell™, an immunotherapeutic created to achieve a functional cure for persistent hepatitis B. For much more data, remember to take a look at www.altimmune.com.

Stick to @Altimmune, Inc. on LinkedIn
Stick to @AltimmuneInc on Twitter

Investor and Media Speak to:

Richard Eisenstadt
Main Money Officer
Cell phone: 240-654-1450
[email protected]